Anupama Kumar, MD

Assistant Professor

Dr. Kumar is hematologist/oncologist who specializes in taking care of patients with hematological malignancies. She completed medical school training and residency at Tufts Medical Center, and hematology/oncology fellowship at University of California, San Diego. She received specialized training through the bone marrow transplant track during her final year of fellowship. Her clinical focus at University of California, San Francisco is multiple myeloma. She takes care of patients in clinic and in the hospital. She leads clinical trials enrolling patients with multiple myeloma.

Education
- Internal Medicine Residency, Tufts Medical Center
M.D., - , Tufts University School of Medicine
- Hematology/Oncology Fellowship, University of California, San Diego
Publications

  1. Chilakapati N, Patiño-Escobar B, Chen EY, Dalal R, de Montagnac J, Johnson H, Kang AS, Akagi N, Ramos E, Phojanakong P, Salangsang F, Zeng Y, Chari A, Chung A, Kumar AD, Martin TG, Wolf JL, Shy BR, Steri V, Karlon WJ, Kortemme T, Barwick BG, Wiita AP. Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma. bioRxiv : the preprint server for biology 2025. PMID: 40894691


  2. Kasap C, Izgutdina A, Patiño-Escobar B, Kang AS, Chilakapati N, Akagi N, Manoj AM, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Aleman A, Wicaksono G, Kelii KMK, Dalal R, Ramos E, Vijayanarayanan A, Lakhani K, Salangsang F, Phojanakong P, Camara Serrano JA, Zakraoui O, Tariq I, Chari A, Chung A, Kumar AD, Martin T, Wolf JL, Wong S, Steri V, Shanmugam M, Boise LH, Kortemme T, Parekh S, Stieglitz E, Licht JD, Karlon W, Barwick BG, Wiita A. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells. Blood 2025. PMID: 40359480


  3. Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S. Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy. Blood 2025. PMID: 40749169


  4. Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs 2025. PMID: 40425184


  5. Davidson J, Kumar A, Patel A, Chen IY, Butte AJ, Zack T. Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence. medRxiv : the preprint server for health sciences 2025. PMID: 40321270


  6. Kumar AD, Chari A. Role of Consolidation and Maintenance. Hematology/oncology clinics of North America 2024. PMID: 38262780


  7. Rath C, Yoo C, Cheplowitz H, Lo M, Young R, Guglielmo J, Saunders IM, Banerjee R, Young R, Kumar A, Chung A, Rosenberg AS, Costello C, Fine J, Wilson M, Patel N, Banez MT. Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2023. PMID: 36731514


  8. Sin NL, Kumar AD, Gehi AK, Whooley MA. Direction of Association Between Depressive Symptoms and Lifestyle Behaviors in Patients with Coronary Heart Disease: the Heart and Soul Study. Volume 50 of Issue 4. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine 2016. PMID: 26817654